PREVAIL 试验:恩扎卢胺治疗化疗初治转移性去势抵抗性前列腺癌的 5 年生存预测与安全性结局
PREVAIL 最终预设分析纳入化疗初治 mCRPC 男性,恩扎卢胺组 689 例、安慰剂组 693 例,中位随访 69 个月。恩扎卢胺降低死亡风险 17%(HR 0.83,95%CI 0.75-0.93,p<0.001),中位总生存 36 个月 vs 31 个月;5 年生存率低、中、高危组分别为 42%、24%、5%。致死性治疗中出现的不良事件恩扎卢胺组 6.9% vs 3.8%,致死性心血管事件 1.6% vs 0.4%。
要点
- 恩扎卢胺较安慰剂降低 mCRPC 死亡风险 17%,中位 OS 延长 5 个月。
- 5 年生存率按预后模型低、中、高危分别为 42%、24%、5%。
- 恩扎卢胺组致死性心血管事件发生率高于安慰剂组(1.6% vs 0.4%)。
核心结论
- 随访超过 5 年,恩扎卢胺在化疗初治 mCRPC 中持续显示生存获益,但致死性心血管事件略高。
研究设计与样本
- PREVAIL 最终预设 5 年生存分析,纳入化疗初治 mCRPC 男性,恩扎卢胺组 n=689,安慰剂组 n=693。
- 采用 Kaplan-Meier 法估计总生存预测因素,并分析长期不良事件随时间的变化。
主要发现
- 5 年数据截止时,1717 例中 1382 例(80%)死亡。
- 恩扎卢胺降低死亡风险 17%(HR 0.83;95%CI 0.75-0.93;p<0.001)。
- 中位总生存恩扎卢胺组 36 个月(95%CI 34-38),安慰剂组 31 个月(95%CI 29-34),中位随访 69 个月。
- 预后模型显示 5 年生存率低危组 42%、中危组 24%、高危组 5%。
- 确认的 PSA 下降(≤3 个月)幅度越大,5 年生存率越高。
关键数值与推荐
- 安慰剂组中分别有 65%、54%、43% 的患者后续接受多西他赛、阿比特龙、恩扎卢胺治疗。
临床怎么用
- 恩扎卢胺可用于化疗初治 mCRPC,治疗前应评估心血管风险并加强监测。
- 可根据预后模型识别 5 年生存率差异大的低、中、高危患者群体。
- 早期 PSA 下降幅度有助于预测长期生存,可作为疗效评估参考。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the PREVAIL study, enzalutamide significantly improved clinical outcomes versus placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To evaluate long-term benefits and risks of enzalutamide in the final prespecified PREVAIL analysis. DESIGN, SETTING, AND PARTICIPANTS: We conducted a final 5-yr survival analysis of PREVAIL in men with chemotherapy-naïve mCRPC from the enzalutamide (n = 689) and placebo (n = 693) arms. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Predictors of the primary outcome of overall survival were estimated using the Kaplan-Meier method. Long-term adverse events over time were analyzed. RESULTS AND LIMITATIONS: At the 5-yr data cutoff, 1382 of 1717 (80%) men had died. Enzalutamide reduced the hazard of death by 17% (hazard ratio 0.83; 95% confidence interval [CI] 0.75-0.93; p < 0.001), despite 65%, 54%, and 43% of placebo-treated patients receiving subsequent docetaxel, abiraterone, and enzalutamide, respectively. Median overall survival was 36 mo (95% CI 34-38) in the enzalutamide arm versus 31 mo (95% CI 29-34) in the placebo arm, with a median follow-up of 69 mo. Prognostic modeling showed 5-yr survival rates of 42%, 24%, and 5% for low-, intermediate-, and high-risk groups, respectively. Greater degrees of confirmed prostate-specific antigen declines (≤3 mo) were associated with greater 5-yr survival. A higher incidence of fatal treatment-emergent adverse events was observed with enzalutamide (6.9% vs 3.8%), with an increase in fatal cardiovascular events (1.6% vs 0.4%). CONCLUSIONS: With >5 yr of follow-up, enzalutamide continued to demonstrate improved survival in patients with mCRPC despite crossover and multiple subsequent effective therapies, balanced against a slightly higher rate of fatal cardiovascular events. PREVAIL is registered on ClinicalTrials.gov as NCT01212991. PATIENT SUMMARY: We report a maintained long-term survival benefit with enzalutamide and risks with >5 yr of enzalutamide treatment and follow-up in men with metastatic prostate cancer, and identify groups of men with widely different outcomes based on clinical factors.
引用
- Armstrong AJ, Lin P, Tombal B, et al. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol. 2020. PMID: 32527692. doi:10.1016/j.eururo.2020.04.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。